Investors

Standardizing Enteral Feeding
Tube Placement

NASDAQ:
FEED

Change:
2.00%

Volume:
$537,542

Price:
$0.43

Last Update: 07-16-2026 19:28

Our Vision

At ENvue, we believe healthcare technology should make patient care safer, simpler, and more efficient.

Our goal is to provide clinicians with reliable tools that improve accuracy and confidence in medical procedures.

By combining innovation with real-world practicality, we help healthcare teams navigate modern challenges with ease.

With ENvue, better patient care is within reach.

News

July 15, 2026

ENvue Medical Appoints Chairman of the Board and New Directors, Bringing Clinical, AI Governance and Capital Markets Expertise to Navigation Platform

READ MORE

July 9, 2026

ENvue Medical Unveils Its First Robotic-Assisted, Artificial Intelligence, Feeding Tube Automation Tool

READ MORE
TO ALL NEWS

Events

?????

Latest Financial Results

10Q – Q1

2026

10K – Annual

2025

10Q – Q3

2024

TO ALL FINANCIAL REPORTS

Contact Us

ENvue Medical (USA) Inc. 762 W. Algonquin Road. Arlington Heights, Illinois 60005, USA

© All rights reserved to ENvue Medical (USA) Inc. 2025

Site by: razgroup

Linkedin-in Envelope

Zeev Rotstein, M.D.

Chairman of the Board

Professor Rotstein’sein is an internationally recognized cardiologist and expert in health management systems with more than four decades of experience spanning clinical leadership, hospital administration, and international health system advisory. Professor Rotstein spent 36 years at Sheba Medical Center in Tel Hashomer, Israel, one of the world’s leading hospitals. He began his career as a senior cardiologist in 1977, served as Deputy Director from 1988 to 1999, and as Director of Sheba’s Acute Care Hospital from 1999 to 2004. From 2004 to 2016, he served as Director General of Sheba Medical Center, during which time the hospital was consistently ranked among the top medical institutions worldwide.

From 2016 to 2021, Professor Rotstein was the Chief Executive Officer and Director General of Hadassah Medical Center in Jerusalem, leading major operational, strategic, and financial restructuring efforts during a challenging period of organizational transformation. Over the course of his career, he has advised multiple public health bodies and contributed to national healthcare policy development in Israel.

Professor Rotstein graduated from the Sackler School of Medicine at Tel Aviv University. He received his Master of Health Administration (MHA) from the Leon Recanti Graduate School of Business Administration at Tel Aviv University and is certified by the Israel Ministry of Health as a specialist in Health Systems Management. Additionally, he has held fellowships at the New York Department of Health, Tufts University, and the Johns Hopkins Bloomberg School of Public Health.

Professor Rotstein’s extensive leadership experience, global reputation, and deep understanding of complex healthcare systems provide him the appropriate experience to serve on the Board.

Zvi Joseph

Director

Mr. Joseph is a seasoned public company director and global legal and compliance executive with more than 20 years of experience advising boards of directors and chief executive officers on corporate governance, enterprise risk, technology, cybersecurity, privacy, executive compensation, and strategic transactions. Throughout his career, he has led global legal organizations and advised companies on technology-driven transformation, mergers and acquisitions, and regulatory compliance.

Mr. Joseph currently serves as an Independent Director of Fabric.ai, Inc. (NASDAQ: FABC), where he serves as Chair of the Compensation Committee and as a member of the Audit Committee and Nominating & Governance Committee. He also serves as an Independent Director of Brenmiller Energy Ltd. (NASDAQ: BNRG), where he serves as Chair of the Compensation Committee and a member of the Audit Committee.

Mr. Joseph currently serves as Head of AI Governance, Risk & Compliance at Amdocs, following more than two decades as Deputy General Counsel. In these roles, he has been responsible for global AI governance, privacy, compliance, intellectual property, employment law, enterprise risk, insurance, disputes, and commercial strategy. He has led global legal teams supporting a multi-billion-dollar business, negotiated strategic transactions and alliances, advised on cybersecurity and regulatory matters, and guided digital transformation and merger and acquisition initiatives.

Earlier in his career, Mr. Joseph was Technology Counsel at Hughes Hubbard & Reed LLP, where he advised clients on intellectual property, technology transactions, outsourcing, licensing, telecommunications, privacy, and enterprise security matters.

Mr. Joseph holds a J.D., cum laude, from Fordham University School of Law and a B.A. from New York University. He has also completed the Advanced Management Program at Harvard Business School and holds the NACD Directorship Certification. Mr. Joseph’s extensive experience in corporate governance, legal strategy, risk management, and public company board oversight provides him the appropriate experience to serve on the Board.

Alison Geiger Burgett

Director

Ms. Geiger Burgett is a seasoned finance executive with more than two decades of leadership experience at publicly held companies, with a proven record of driving value creation, profitability, and strategic transformation. She currently serves as Chief Financial Officer of AgEagle Aerial Systems (NYSE: UAVS), a drone and sensor manufacturer, where she leads financial planning, budgeting, forecasting, and capital structure management. At AgEagle, Ms. Geiger Burgett secured $12 million in funding, streamlined financial operations, and implemented internal controls to strengthen financial reporting, compliance, and operational efficiency.

Prior to AgEagle, Ms. Geiger Burgett spent five years at Centene Corporation (NYSE: CNC), a $143.7 billion managed care company, where she held multiple senior finance leadership roles, including Senior Director of Finance and Strategic Initiatives, Senior Director of Finance and Quality Improvement, and Director of Finance and Performance Management. In these roles, she oversaw strategic budgeting, value capture, ROI analysis, and large-scale quality improvement initiatives across multiple states and business units. She also managed a $470 million corporate quality budget and served as a financial liaison to 39 state partners.

Earlier in her career, Ms. Geiger Burgett held finance leadership positions at Republic Services, Inc. (NYSE: RSG), where she led contract optimization initiatives that generated $30 million in increased revenue and savings. She also spent more than a decade at Providence Service Corporation (NASDAQ: PRSC), where she played a key role in multiple acquisitions and divestitures, standardizing consolidation processes and leading integration of global entities.

Ms. Geiger Burgett holds a Master of Business Administration from Boise State University and a Bachelor of Science in Accounting from the University of Phoenix. Her extensive financial leadership experience, capital markets expertise, and operational discipline provide her the appropriate experience to serve on the Board.

Doron Besser, M.D.

Chief Executive Officer and Director

Dr. Doron Besser is the Chief Executive Officer and President of ENvue Medical, bringing more than two decades of leadership experience in medical device innovation, strategic commercialization, and organizational growth. Prior to ENvue, Dr. Besser served as Chief Executive Officer of Angioslide Ltd., a company specializing in innovative, cost-effective angioplasty products. Under his leadership, Angioslide advanced from early-stage development through complicated animal and human trials, achieving FDA clearance, CE approval, and initial commercial penetration in both the European and U.S. markets.

Dr. Besser also served as Vice President of Clinical and Marketing and Vice President of Business Development at superDimension, a leader in minimally invasive pulmonology devices. He was a member of the company’s founding team and played a central role in identifying market opportunities, building clinical and commercial strategy, and positioning superDimension as a leader in navigational bronchoscopy. In 2012, Covidien acquired superDimension for approximately $300 million.

Throughout his career, Dr. Besser has focused on identifying breakthrough technologies and developing them through every stage of product development – from concept and regulatory clearance to commercialization and scale. He has extensive experience working with cross-functional teams spanning R&D, clinical, regulatory, and commercial operations, as well as engaging with investors and strategic partners.

Dr. Besser holds a Doctor of Medicine degree from Munich’s Ludwig-Maximilians University. His extensive leadership experience in the healthcare industry, combined with a proven record of innovation, commercialization, and strategic execution, provides him the appropriate experience to serve on the Board.

Lior Buchman

Director

Mr. Buchman is a Certified Public Accountant (CPA) and finance executive with more than 20 years of experience leading corporate finance, fundraising, strategic transactions, and financial operations across venture-backed technology companies and investment platforms. Throughout his career, he has executed more than $320 million in fundraising, mergers and acquisitions, financing transactions, strategic partnerships, and licensing agreements, and has led IPO preparation and marketing activities. He has also built finance and operating infrastructures, including financial planning and analysis, treasury, internal controls, reporting systems, and cross-border corporate structures, while working closely with boards of directors, investors, and executive management.

From 2016 to 2025, Mr. Buchman held senior leadership positions at Integra Holdings, an investment and venture creation platform affiliated with the Hebrew University of Jerusalem’s technology transfer company, Yissum. He served as Chief Executive Officer from 2022 to 2025, where he led portfolio strategy, venture creation, investment evaluation, financing activities, and portfolio company governance. Previously, as Chief Financial Officer, he led IPO readiness and investor marketing activities, secured platform investments from institutional investors, negotiated strategic partnerships and licensing agreements, and established the organization’s finance and reporting infrastructure.

Prior to joining Integra Holdings, Mr. Buchman served as Chief Financial Officer of Orpheus Medical Ltd., Keystone Heart Ltd., and NiTi Surgical Solutions Inc., where he was responsible for financial strategy, fundraising, international financial operations, corporate governance, and supporting the growth of each organization. Earlier in his career, he held senior finance leadership positions at Sightline Technologies Ltd., which was subsequently acquired by Stryker Corporation, and later led finance, administration, and IT for the integrated business following the acquisition.

Mr. Buchman is a Certified Public Accountant (CPA) and holds a B.A. in Accounting and Economics from the University of Haifa. Mr. Buchman’s extensive experience in corporate finance, capital raising, strategic transactions, and financial leadership provides him the appropriate experience to serve on the Board.

Marc Waldman

VP Commercial

Marc Waldman has over 35 years of experience in the medical device industry, including nearly a decade with NeoMed and Avanos Medical, where he served as North America Sales Director for the neonatal enteral feeding portfolio. In this role, he led a national team, expanded key accounts, guided a transition to a hybrid direct/dealer model, and grew revenue from approximately $39M to $70M in three and a half years.

Previously, Marc was Principal of West Branch Medical, helping build it into a multimillion-dollar maternal-child health distributor, and held commercial leadership roles at Wren Medical, NOW Medical, Day & Zimmermann, and Vital Signs.

He currently serves as Chairperson of GEDSA, advancing enteral safety standards across the U.S. healthcare system.

Rita Silberberg

Chief Financial Officer

Rita Silberberg is an accomplished financial officer with over 15 years of proven experience in corporate strategy, international tax planning, and managing corporate financial teams as well as outside contractors.

Before joining ENvue Medical in 2022, she served as CFO at Gravity Creative Space, controller at novoGI, firm controller and project manager at Ernst & Young, and more. She is closely familiar with accounting regulations including US GAAP and IFRS, and has worked with multinational firms around the globe.

Rita holds a BA in business specializing in accounting, as well as an LL.B in accounting and finance, both from the College of Management.

Fred Reuning

Chief Marketing Officer

Before joining ENvue Medical in 2018, Fred served as North America medical device marketing lead at Nestle Health Sciences US, as VP of the endovenous laser business (VariLase) at Vascular Solutions, and as director of marketing vascular access products at Smiths Medical.

Fred Reuning is a medical device marketing executive with vast experience in radiology, cardiology, infusion therapy, and enteral nutrition markets, and expertise in marketing disposable products, implantable devices, and capital equipment. Fred has launched over 30 products over a 25-year+ career.

He holds a BA in history from Washington and Lee University, and an MA from Johns Hopkins University.

Anat Hofshi, PhD

VP Clinical Affairs & Product

With a great belief in technologies that can improve patient safety, Dr. Hofshi joined ENvue Medical in 2016 to lead the clinical activities and trials required to finalize the R&D phase and to commercialize the ENvue system in the US. Dr. Hofshi brings outstanding ability to interconnect between different disciplines areas and a high level of practical and hands-on skills.

Previous to her joining ENvue, Dr. Hofshi, served as a Project Leader at B.G. Guard and Carmel StemSense, startup companies in the field of Diabetics.

Dr. Hofshi holds a B.S.c in Biotechnology and Food engineering and a PhD from the Department of Physiology and Biophysics, Technion Institute, specializing in Electrophysiology, Stem Cells and Cardiovascular Regenerative Medicine. Dr. Hofshi received many awards and honors for her scientific accomplishments (Wolf, etc.).

Zenya Gorlik

VP R&D

Zenya Gorlik is a seasoned software expert with over 20 years of experience in developing large-scale multidisciplinary projects in military and medical industries from geographic information systems for intelligence to MRI medical devices and beyond.  He specializes in managing projects end-to-end from concept to delivery.

Before joining ENvue Medical in 2021, Zenya served as senior software engineer and team leader at Camtek, ImageSat International, and Aspect Imaging, as software consultant at CodeValue, and more.

He holds a BA in mathematics and computer science from Haifa University, and is certified as a systems analysis engineer by the Technion Institute of Technology.

Nicole Fernandez-McGovern

CFO

Nicole Fernandez-McGovern serves as Chief Financial Officer of ENvue Medical, Inc. (Nasdaq: FEED), a publicly traded medical technology company. She brings more than 25 years of experience in finance, operations, and strategic leadership across public and private companies, with deep expertise in capital markets transactions, mergers and acquisitions, and operational transformation.

Prior to joining ENvue Medical, Ms. Fernandez-McGovern served as Chief Financial Officer of NLS Pharmaceutics Ltd. (Nasdaq: NLSP), where she led the company through its merger with Kadimastem Ltd., resulting in the formation of NewCelX Ltd. (Nasdaq: NCEL). She also served as Interim Chief Financial Officer of Hayden AI, supporting capital raises totaling $115 million and contributing to the execution of a $700 million government contract. From 2016 to 2023, she served as Chief Financial Officer and Executive Vice President of Operations of AgEagle Aerial Systems, Inc. (NYSE: UAVS), overseeing global financial, operational, and manufacturing functions. Earlier in her career, she served as Chief Executive Officer and Chief Financial Officer of Trunity Holdings, Inc., and held corporate accounting, audit, and finance positions at Elizabeth Arden, Inc., Ryder System, Inc., and KPMG LLP.

Ms. Fernandez-McGovern has completed more than $200 million in M&A and equity financings over her career and has also served on the boards of other public and nonprofit organizations, including MGO Global, Inc., which recently completed a reverse merger to become Heidmar, and Pembroke Pines Charter School. She currently serves on the board of Financial Executives International (FEI). She holds a Bachelor of Business Administration and a Master of Business Administration from the University of Miami and has been a licensed Certified Public Accountant in Florida since 1998. She is fluent in Spanish.

Doron Besser, M.D.

Chief Executive Officer

Doron Besser is the CEO of ENvue Medical and NanoVibronix (Nasdaq: NAOV), overseeing the integration of the two divisions: electromagnetic navigation for enteral feeding (ENvue) and non-invasive therapeutic devices for pain and urology (NanoVibronix).

Doron is continuing the advancement and commercialization of ENvue navigation system for enteral feeding, leading global strategy, clinical education, commercialization in the U.S. and ROW, and expansion into new applications including pediatrics and vascular access.
Prior to managing both divisions, Doron co-founded and managed ENvizion Medical and Swing Medical, a private equity investment fund. Doron guided ENvizion Medical from concept to FDA clearance, built U.S. clinical adoption, and launched the ENvue system into hospitals as a next-generation navigation platform.

Doron also co-founded and led NutriSeal, a company focused on preventing nasoenteral-induced gastric reflux and ventilator-associated pneumonia (VAP). Prior to NutriSeal, Doron served as CEO of Angioslide Ltd., a company specializing in innovative, cost effective angioplasty products. Doron guided the company through its infancy stages, which included complicated animal and human trials, to FDA clearance, CE approval and initial market penetration in Europe and the US. Doron also served as VP of Clinical and Marketing and VP of Business Development at super Dimension, a leader in minimally-invasive pulmonology devices. Doron helped lead super Dimension from its inception, serving on the core team that identified opportunities within the pulmonology market. In 2012, Covidien acquired superDimension for ~$300 million.

As a seasoned entrepreneur, Doron specializes in identifying breakthrough technologies and developing them throughout all product development phases, including international sales and marketing activities.

He holds a Doctor of Medicine degree from Munich’s Ludwig-Maximilians University.